GSA Capital Partners’s Rani Therapeutics RANI Stock Holding History
Bought
Maintained
Sold
Other funds holding RANI
AIC
SL
GSA Capital Partners's RANI Position: Q3 2026 in Review
GSA Capital Partners increased its Rani Therapeutics (RANI) stake by 320% in Q3 2026, buying an estimated $638K and bringing the position to 1,049,321 shares worth $830K. The position accounts for 0.05% of the portfolio, ranked #705.
GSA Capital Partners first reported a position in RANI in Q1 2025 and has held it in 5 quarters since. 68 funds tracked by Wall St. Rank hold RANI as of Q3 2026.
- GSA Capital Partners held 1,049,321 shares of Rani Therapeutics worth $830K as of Q3 2026.
- GSA Capital Partners bought 799,605 Rani Therapeutics shares in Q3 2026, an estimated $638K.
- Rani Therapeutics made up 0.05% of GSA Capital Partners's portfolio in Q3 2026, its #705 holding.
- GSA Capital Partners first reported a position in Rani Therapeutics in Q1 2025 and has held it in 5 quarters since.
- 68 funds tracked by Wall St. Rank held Rani Therapeutics as of Q3 2026.
Based on GSA Capital Partners's 13F filing for Q3 2026, filed 16 Nov 2026.